ICAM‐1 Activates Platelets and Promotes Endothelial Permeability through VE‐Cadherin after Insufficient Radiofrequency Ablation

• Main Authors: Jian Kong, Changyu Yao, Shuying Dong, Shilun Wu, Yangkai Xu, Ke Li, Liang Ji, Qiang Shen, Qi Zhang, Rui Zhan, Hongtu Cui, Changping Zhou, Haigang Niu, Guoming Li, Wenbing Sun, Lemin Zheng
• Format: Article
• Language: English
• Published: Wiley 2021-02-01
• Series: Advanced Science
• Subjects: endothelial permeability; hepatocellular carcinoma; ICAM‐1; platelets; radiofrequency ablation
• Online Access: https://doi.org/10.1002/advs.202002228

Abstract Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) often leads to aggressive local recurrence and increased metastasis, and vascular integrity and platelets are implicated in tumor metastasis. However, whether interactions between endothelial cells and platelets induce endothelial permeability in HCC after insufficient RFA remains unclear. Here, significantly increased CD62P‐positive platelets and sP‐selectin in plasma are observed in HCC patients after RFA, and tumor‐associated endothelial cells (TAECs) activate platelets and are susceptible to permeability after heat treatment in the presence of platelets in vitro. In addition, tumors exhibit enhanced vascular permeability after insufficient RFA in mice; heat treatment promotes platelets‐induced endothelial permeability through vascular endothelial (VE)‐cadherin, and ICAM‐1 upregulation in TAECs after heat treatment results in platelet activation and increased endothelial permeability in vitro. Moreover, the binding interaction between upregulated ICAM‐1 and Ezrin downregulates VE‐cadherin expression. Furthermore, platelet depletion or ICAM‐1 inhibition suppresses tumor growth and metastasis after insufficient RFA in an orthotopic tumor mouse model, and vascular permeability decreases in ICAM‐1−/− mouse tumor after insufficient RFA. The findings suggest that ICAM‐1 activates platelets and promotes endothelial permeability in TAECs through VE‐cadherin after insufficient RFA, and anti‐platelet and anti‐ICAM‐1 therapy can be used to prevent progression of HCC after insufficient RFA.